Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis

Journal of Investigative Dermatology

Volumn 126, Issue 6, 2006, Pages 1366-1371

  Fecker, Lothar F ^a   Geilen, Christoph C ^a   Tchernev, Georgi ^a   Trefzer, Uwe ^a   Assaf, Chalid ^a   Kurbanov, Bachtier M ^a   Schwarz, Constanze ^a   Daniel, Peter T ^a   Eberle, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BOK; PROTEIN MCL 1; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BAK1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE REGULATION; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MELANOMA; MITOCHONDRION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR GROWTH; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SKIN TUMOR;

AGED; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745583838     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700192     Document Type: Article

References (30)

1. Bachmann IM, Straume O, Akslen LA (2004) Altered expression of cell cycle regulators cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol 25:1559-65
2. Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902-8
3. Clark WH Jr, From L, Bernardino EA, Mihm MC (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705-27
4. Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647-56
5. Dadras SS, Lange-Asschenfeldt B, Velasco P, Nguyen L, Vora A, Muzikansk A et al. (2005) Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 18:1232-42
6. Daniel PT, Schulze-Osthoff K, Belka C, Guner D (2003) Guardians of cell death: the Bcl-2 family proteins. Essays Biochem 39:73-88
7. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K (2001) The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 15:1022-32
8. Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE et al. (2003) CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 22:9131-41
9. Eigentler TK, Buettner PG, Leiter U, Garbe C (2004) Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. J Clin Oncol 22:4376-83
10. Fecker LF, Geilen CC, Hossini AM, Schwarz C, Fechner H, Bartlett DL et al. (2005) Selective induction of apoptosis in melanoma cells by tyrosinase promoter-controlled CD95 ligand overexpression. J Invest Dermatol 124:221-8
11. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M et al. (1998) Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43:414-21
12. Garbe C, Blum A (2001) Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 14:280-90
13. Georgieva J, Sinha P, Schadendorf D (2001) Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 54:229-35
14. Guner D, Sturm I, Hemmati P, Hermann S, Hauptmann S, Wurm R et al. (2003) Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. Int J Cancer 103:445-54
15. Hossini AM, Eberle J, Fecker LF, Orfanos CE, Geilen CC (2003) Conditional expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts. FEBS Lett 553:250-6
16. Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ (1997) Bok is a proapoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc Natl Acad Sci USA 94:12401-6
17. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T et al. (2000) Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356:1728-33
18. Korabiowska M, Ruschenburg I, Betke H, Stachura J, Schlott T, Cardo CC et al. (2001) Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma. Pathobiology 69:274-80
19. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E et al. (1995) Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471-8
20. Mandic A, Viktorsson K, Molin M, Akusjarvi G, Eguchi H, Hayashi SI et al. (2001) Cisplatin induces the proapoptotic conformation of Bak in a deltaMEKK1 -dependent manner. Mol Cell Biol 21:3684-91
21. Oppermann M, Geilen CC, Fecker LF, Gillissen B, Daniel PT, Eberle J (2005) Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk/Bik. Oncogene 24:7369-80
22. Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I et al. (2001) The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 117:333-40
23. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22:3138-51
24. Sprick MR, Walczak H (2004) The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 1644:125-132
25. Straume O, Sviland L, Akslen LA (2000) Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 6:1845-53
26. Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA (1998) BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 16:2583-90
27. Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G et al. (1998) Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 4:1865-71
28. Thallinger C, Wolschek MF, Wacheck V, Maierhofer H, Gunsberg P, Polterauer P et al. (2003) Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 120:1081-6
29. Vousden KH (2002) Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602:47-59
30. Yakovlev AG, Di Giovanni S, Wang G, Liu W, Stoica B, Faden AI (2004) BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem 279:28367-74